Article Text

Download PDFPDF
Expression of peroxisome proliferator activated receptor γ and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma
  1. Sylvia Stadlmann1,
  2. Uwe Gueth2,
  3. Edward Wight2,*,
  4. Leoni A Kunz-Schughart3,
  5. Arndt Hartmann3,
  6. Gad Singer1,*
  1. 1Institute of Pathology, University Hospital Basel, Basel, Switzerland
  2. 2Department of Gynecology and Obstetrics, University Hospital Basel, Basel, Switzerland
  3. 3Institute of Pathology, University of Regensburg, Regensburg, Germany
  1. Correspondence to:
 PD Dr G Singer
 Institute of Pathology, University Hospital Basel, Schönbeinstrasse 40, CH-4031 Basel, Switzerland; gsinger{at}


Aim: Peroxisome proliferator-activated receptor γ (PPARγ) has emerged as a potential therapeutic target in several types of cancer. In ovarian carcinomas, limited and conflicting data on PPARγ protein expression have been reported.

Methods: The immunoexpression of PPARγ and its putative target cyclo-oxygenase 2 (COX2) was investigated in tumour tissues from 80 patients with primary and corresponding recurrent ovarian serous carcinomas after conventional platinum-based chemotherapy.

Results: PPARγ expression was observed in 29% of primary and recurrent carcinomas. In the recurrent tumours, PPARγ expression inversely correlated with COX2 overexpression in both chemosensitive (p = 0.02) and chemoresistant (p = 0.04) carcinomas.

Conclusions: The data indicate that PPARγ may represent a potential target for second-line treatment in ovarian cancers.

  • COX2, cyclo-oxygenase 2
  • IHC, immunohistochemistry
  • PPARγ, peroxisome proliferator-activated receptor γ
  • TMA, tissue microarray

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Published Online First 12 May 2006

  • * These authors have contributed equally to the work.

  • Funding: This study was supported by the Swiss Cancer League (Oncosuisse), grant number OCS 01506-02-2004.

  • Competing interests: None declared.